Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PCNA | P12004 | 1/20 | 0.41 |
| ▸ | LIG1 | P18858 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291507 | 1.00 | LOXL2 (0.51) | LOXL2LTA4HADRB2PDPK1FFAR1 | |
| SCHEMBL2291027 | 0.83 | LTA4H (0.51) | LOXL2LTA4HPDPK1FFAR1PCNA | |
| SCHEMBL2291017 | 0.83 | LTA4H (0.51) | LOXL2LTA4HPDPK1FFAR1PCNA | |
| SCHEMBL28579042 | 0.81 | PDPK1 (0.61) | LOXL2LTA4HADRB2PDPK1FFAR1 | |
| SCHEMBL22530451 | 0.76 | LOXL2 (0.54) | LOXL2LTA4HADRB2PDPK1SLC6A4 | |
| SCHEMBL2295510 | 0.76 | PDPK1 (0.52) | LOXL2LTA4HADRB2PDPK1FFAR1 | |
| SCHEMBL12379273 | 0.75 | LTA4H (0.53) | LOXL2LTA4HADRB2PDPK1FFAR1 | |
| SCHEMBL6869224 | 0.74 | LOXL2 (0.53) | LOXL2LTA4HADRB2PDPK1FFAR1 | |
| SCHEMBL12379270 | 0.74 | LTA4H (0.50) | LOXL2LTA4HADRB2FFAR1SCN9A | |
| SCHEMBL7606167 | 0.73 | LOXL2 (0.55) | LOXL2ADRB2PDPK1FFAR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989480-B2 | Aryl amino acid derivatives as inhibitors for treating inflammation | DECODE GENETICS EHF (IS) | 2011-08-02 | — | — | US | disclosed |
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | LTA4H, LTB4R2, LTB4R | LOXL2 108/4885LTA4H 1/4885ADRB2 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.